P1.21-11 Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%
Journal of Thoracic Oncology(2023)
Abstract
Immunotherapy Response Score (IRS) is a tissue-based multivariable algorithm previously validated to predict anti-PD-(L)1 benefit pan-tumor (PMID:36750617) from routine tissue samples. We evaluated IRS in an independent cohort of Kaiser Permanente Northern California (KPNC) patients with advanced non-small cell lung cancer (NSCLC) following a pre-specified statistical analysis plan for the primary objective.
MoreTranslated text
Key words
pembrolizumab clinical benefit,immunotherapy response score,immunotherapy response
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined